Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Acuta Capital Partners



Unlock datapoints

Portfolio analytics


News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 11
Average round size
The average size of a deal this fund participated in
Portfolio companies 11
Lead investments 0
Exits 5
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Biopharma
  • Pharmaceutical

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Acuta Capital Partners, startups are often financed by Xeraya Capital, OrbiMed, Kearny Venture Partners. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, RA Capital Management, Puissance Capital.

We also calculated 3 valuable employees in our database.

The top amount of exits for fund were in 2016. Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2017.

Among the most popular fund investment industries, there are Therapeutics, Pharmaceutical. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline ViewRay, Kadmon

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Acuta Capital Partners:
Typical Co-investors
Acuta Capital Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Acuta Capital Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ABB Switzerland, Zürich, Zurich
Aston Partners New York, New York, United States
Beresford Ventures Delray Beach, Florida, United States
Cobis Great Falls, United States, Virginia
Coinsilium Group England, London, United Kingdom
Gabriel Capital Management New York, New York, United States
Greater Manchester AI Foundry England, Manchester, United Kingdom
Hybio Pharmaceutical China, Guangdong, Shenzhen
Kettle Partners Chicago, Illinois, United States
Next Road Ventures Mazowieckie, Poland, Warsaw
Sistema Investimenti Catania, Italy, Sicilia
Starharbor Asia -
Sumitomo Chemical Japan, Tokyo
Telos Ventures California, Redwood City, United States
TNP Threads Of Light Japan, Kanagawa Prefecture, Yokohama
TPG Growth California, San Francisco, United States
Xinlan Investment Beijing, Changping, China
Yizheng Tiandao Beijing, Beijing, China

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

GH Research Closes $125M Series B Financing

– GH Research Ireland Ltd is a Dublin, Ireland-based clinical-stage biopharmaceutical company.
– The company closed a $125m Series B funding.
– The round was co-led by RA Capital and RTW Investments, LP, with participation from existing investor BVF Partners, and new backers Acuta Capital Partners, Boxer Capital, Cormorant Asset Management, Deerfield Management Company, Logos Capital, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners and Verition Fund Management.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Acuta Capital Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 11
Average round size 105M
Peak activity year 2020
Lead investments 0
Exits 5
Group Appearance index 1.00
Crunchbase icon

Content report

The following text will be sent to our editors: